UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Brief description of study

Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
 



Detailed description of study

The main purpose of this study is to test the safety of an oral drug, ibrutinib, added to the standard lymphoma treatment.
 We will also study whether ibrutinib has a helpful effect against HIV and other viruses in our bodies that can cause lymphoma.

Additional Information
If you meet all of the criteria for being in the study, you will be registered to participate. Trial participation includes one-5 day inpatient stay each treatment cycle. Each treatment cycle is 21 days.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-Hodgkin lymphoma,Diffuse Large B-cell Lymphoma,HIV+,
  • Age: Between 18 Years - 64 Years
  • Gender: All

  1. Participants must have documented CD20 positive or negative diffuse large B-cell lymphoma (DLBCL).
  2. Stage II-IV disease.
  3. Documentation of HIV diagnosis.
  4.  Be 18–64 yrs of age.

Updated on 09 Mar 2024. Study ID: 828995

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center